We Her2 3+ are very fortunate indeed to have so many treatments available, and more in the pipeline.
Thank you Lani for posting this.
For more detail:
Journal of Oncology
Volume 2013 (2013), Article ID 732047, 12 pages
http://dx.doi.org/10.1155/2013/732047
http://www.hindawi.com/journals/jo/2013/732047/